Kurt M. Eichler is Director at Spring Bank Pharmaceuticals, Inc. (SBPH). They have made 12 open-market trades across 3 companies since 2009, most recently 2019-12-30.
CIK 0001424591
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
11 open-market purchases totalling $1.7M since 2009, against 1 sale. Across 10 scored buys the stock is down 9.6% at ninety days, and 12.8 points behind the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 70% | 40% | 30% |
| Avg Move | +3.3% | -1.3% | -9.6% |
| Alpha | +3.2% | -2.0% | -12.8% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SBPH | SELL | 2019-12-30 | 2020-01-02 | $1.26 | $50K | -10.0% | -25.6% | -43.9% |
| SBPH | BUY | 2017-06-27 | 2017-06-27 | $13.00 | $1000K | +16.3% | +5.7% | +18.7% |
| SBPH | BUY | 2017-02-23 | 2017-02-27 | $8.76 | $11K | +6.1% | -6.7% | +35.5% |
| SBPH | BUY | 2016-11-09 | 2016-11-10 | $8.69 | $61K | +9.8% | -5.2% | -6.8% |
| SBPH | BUY | 2016-09-16 | 2016-09-20 | $12.50 | $25K | +0.0% | -10.6% | -36.0% |
| SBPH | BUY | 2016-09-14 | 2016-09-15 | $12.50 | $6K | -5.2% | -13.9% | -32.8% |
| SBPH | BUY | 2016-09-13 | 2016-09-14 | $12.50 | $6K | +3.8% | -4.9% | -37.4% |
| SBPH | BUY | 2016-08-23 | 2016-08-24 | $10.73 | $32K | +6.0% | +5.8% | -26.3% |
| SBPH | BUY | 2016-08-04 | 2016-08-05 | $9.79 | $10K | +1.9% | +17.8% | -10.0% |
| SBPH | BUY | 2016-05-11 | 2016-05-12 | $12.00 | $500K | +1.8% | +0.9% | +1.1% |
| MDXG | BUY | 2010-12-31 | 2011-01-04 | $0.99 | $50K | -7.9% | -2.1% | -2.1% |
| MDXG.OB | BUY | 2009-10-19 | 2009-10-21 | $0.45 | $7K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.